Short‑term efficacy and safety of prednisone in herpes zoster and the effects on IL‑6 and IL‑10

Peng,Lixin; Du,Bin; Sun,Liangliang; Zhao,Yuguang; Zhang,Xinping

doi:10.3892/etm.2019.7898

Short‑term efficacy and safety of prednisone in herpes zoster and the effects on IL‑6 and IL‑10

Authors:
- Lixin Peng
- Bin Du
- Liangliang Sun
- Yuguang Zhao
- Xinping Zhang
View Affiliations

Affiliations: Department of Dermatology, Daqing Oilfield General Hospital, Daqing, Heilongjiang 163001, P.R. China
Published online on: August 14, 2019 https://doi.org/10.3892/etm.2019.7898
Pages: 2893-2900

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Short‑term efficacy and safety of prednisone in herpes zoster and the effect on IL‑6 and IL‑10 were investigated. A total of 125 patients (aged 40‑70 years) with acute infective herpes zoster who were admitted to Daqing Oilfield General Hospital were selected and divided into 3 groups according to different treatment methods: low‑dose (n=44), middle‑dose (n=42) and high‑dose (n=39) groups. The therapeutic effect, visual analogue scale (VAS) pain score, pain relieving and disappearing time, herpes stopping and disappearing time, incrustation and decrustation time, and incidence of adverse reactions in the three groups were recorded. The changes of IL‑6 and IL‑10 levels in the peripheral blood of patients before and after treatment were detected by enzyme‑linked immunosorbent assay (ELISA) in order to analyze their relationship with pain degree and the time of symptom remission and subsidence. There were no significant differences in cure rate, significant effective rate, effective rate, ineffective rate and total effective rate among the three groups (P>0.05). The pain relieving and disappearing time in the middle‑dose group were shorter than those in the low‑ and high‑dose groups (P<0.05). The levels of IL‑6 and IL‑10 showed no statistical differences in the 3 groups before treatment (P>0.05). Pearson correlation analysis showed that IL‑6 was positively correlated with VAS pain score, pain relieving and disappearing time, herpes stopping and disappearing time, incrustation and decrustation time (P<0.05), while IL‑10 was negatively correlated with the above indicators (P<0.05). In conclusion, middle‑dose prednisone has similar short‑term efficacy to high‑dose prednisone in the treatment of herpes zoster, but with lower complication and higher safety. IL‑6 and IL‑10 are closely related to the pain degree and the time of symptom remission and subsidence, which may provide a reference for clinical evaluation of the therapeutic effect of patients with herpes zoster.

View Figures

View References

1	Harpaz R, Ortega-Sanchez IR and Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control Prevention (CDC), : Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 57:1–30; quiz CE2-CE4. 2008.PubMed/NCBI
2	Cohen JI: Clinical practice: Herpes zoster. N Engl J Med. 369:255–263. 2013. View Article : Google Scholar : PubMed/NCBI
3	Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou V, Rentier B, Rümke H, Sadzot-Delvaux C, Senterre J, et al: Varicella vaccination in Europe - taking the practical approach. BMC Med. 7:26. 2009. View Article : Google Scholar : PubMed/NCBI
4	Johnson RW: Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 9 (Suppl):21–26. 2010. View Article : Google Scholar : PubMed/NCBI
5	Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL and Griffiths PD: Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 48 (Suppl 1):S2–S7. 2010. View Article : Google Scholar : PubMed/NCBI
6	Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K and Acosta CJ: Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis. 15:502. 2015. View Article : Google Scholar : PubMed/NCBI
7	Pinchinat S, Cebrián-Cuenca AM, Bricout H and Johnson RW: Similar herpes zoster incidence across Europe: Results from a systematic literature review. BMC Infect Dis. 13:170. 2013. View Article : Google Scholar : PubMed/NCBI
8	Nordgaard-Lassen I, Dahlerup J F, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, Ravn P, Sørensen IJ, Theede K and Tjellesen L: Danish Society for Gastroenterology. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 59:C44802012.PubMed/NCBI
9	Levin MJ: Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections. J Clin Virol. 61:487–495. 2014. View Article : Google Scholar : PubMed/NCBI
10	Han Y, Zhang J, Chen N, He L, Zhou M and Zhu C: Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 1:CD0055822013.
11	Ernst P, Dell'Aniello S, Mikaeloff Y and Suissa S: Risk of herpes zoster in patients prescribed inhaled corticosteroids: A cohort study. BMC Pulm Med. 11:592011. View Article : Google Scholar : PubMed/NCBI
12	Zhao B: Clinical Dermatology in China. Jiangsu Science and Technology Press; pp. 613–618. 2010
13	Marra F, Lo E, Kalashnikov V and Richardson K: Risk of herpes zoster in individuals on biologics, DMARDS and/or corticosteroids for autoimmune diseases: A systematic review and meta-analysis. Open Forum Infect Dis. 3:ofw2052016. View Article : Google Scholar : PubMed/NCBI
14	Long MD, Martin C, Sandler RS and Kappelman MD: Increased risk of herpes zoster among 108,604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 37:420–429. 2013. View Article : Google Scholar : PubMed/NCBI
15	Anderson DJ and Janoff EN: Herpes zoster infection in a patient on methotrexate given prednisone to prevent post-herpetic neuralgia. Ann Intern Med. 107:783. 1987. View Article : Google Scholar : PubMed/NCBI
16	Clemmensen OJ and Andersen KE: ACTH versus prednisone and placebo in herpes zoster treatment. Clin Exp Dermatol. 9:557–563. 1984. View Article : Google Scholar : PubMed/NCBI
17	Whitley RJ, Weiss H, Gnann JW Jr, Tyring S, Mertz GJ, Pappas PG, Schleupner CJ, Hayden F, Wolf J and Soong SJ; The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, : Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. Ann Intern Med. 125:376–383. 1996. View Article : Google Scholar : PubMed/NCBI
18	Jeon YH: Herpes zoster and postherpetic neuralgia: Practical consideration for prevention and treatment. Korean J Pain. 28:177–184. 2015. View Article : Google Scholar : PubMed/NCBI
19	Heatrice A II, Alavi M, Han PP and Enciso R: Oral corticosteroid therapy for preventing postherpetic neuralgia: A systematic review and meta-analysis. Open J Dent Oral Med. 5:47–57. 2017.
20	Rygård SL, Butler E, Granholm A, Møller MH, Cohen J, Finfer S, Perner A, Myburgh J, Venkatesh B and Delaney A: Low-dose corticosteroids for adult patients with septic shock: A systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 44:1003–1016. 2018. View Article : Google Scholar : PubMed/NCBI
21	Sugimoto S, Miyoshi K, Kurosaki T, Otani S, Yamane M, Kobayashi M and Oto T: Favorable survival in lung transplant recipients on preoperative low-dose, as compared to high-dose corticosteroids, after hematopoietic stem cell transplantation. Int J Hematol. 107:696–702. 2018. View Article : Google Scholar : PubMed/NCBI
22	Izquierdo JL and Cosio BG: The dose of inhaled corticosteroids in patients with COPD: When less is better. Int J Chron Obstruct Pulmon Dis. 13:3539–3547. 2018. View Article : Google Scholar : PubMed/NCBI
23	Daley-Yates PT: Inhaled corticosteroids: Potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 80:372–380. 2015. View Article : Google Scholar : PubMed/NCBI
24	Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, et al: The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Ann Rheum Dis. 74:480–489. 2015. View Article : Google Scholar : PubMed/NCBI
25	Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, Saag KG, Singh J and Curtis JR: Risk of herpes zoster in autoimmune and inflammatory diseases: Implications for vaccination. Arthritis Rheumatol. 68:2328–2337. 2016. View Article : Google Scholar : PubMed/NCBI
26	Shi HJ and Cui ZQ: Correlation of serum inflammatory cytokine and immunoglobulin content with post-herpetic neuralgia in patients with acute herpes zoster. Hainan Yixueyuan Xuebao. 23:97–100. 2017.(In Chinese).
27	Huang PC, Tsai KL, Chen YW, Lin HT and Hung CH: Exercise combined with ultrasound attenuates neuropathic pain in rats associated with downregulation of IL-6 and TNF-α, but with upregulation of IL-10. Anesth Analg. 124:2038–2044. 2017. View Article : Google Scholar : PubMed/NCBI
28	Leung A, Gregory NS, Allen LAH and Sluka KA: Regular physical activity prevents chronic pain by altering resident muscle macrophage phenotype and increasing interleukin-10 in mice. Pain. 157:70–79. 2016. View Article : Google Scholar : PubMed/NCBI